CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective hard but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire employment interview which I came away with a poor viewpoint of the company.

Irony of irony, the poor impression of mine of the company has grown steadily, however, the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of this know-how and associated intellectual property from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) and the first new drug application approval ($5 million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and multiple therapies, it’s this individual therapies as well as a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on its site (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple illness sorts, multiple delivering presentations and multiple publications.

Could all of it be smoke and mirrors? That is a question I’ve been asking myself from the very start of my interest in this company. Judging with the multiples of thousands of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

This entry was posted in Health. Bookmark the permalink.